User login
Key clinical point: Risk for overall cancer was 17% higher and cancer-specific mortality 26% higher in patients with inflammatory bowel disease (IBD) compared with non-IBD individuals.
Major finding: Risk for overall cancer (adjusted hazard ratio [aHR] 1.17; P < .001), particularly digestive cancer (aHR 1.33; P = .001), skin cancer (aHR 1.25; P < .001), and male genital cancer (aHR 1.29; P = .003), and cancer-specific mortality (aHR 1.26; P < .001) was significantly higher among patients with IBD vs. non-IBD individuals.
Study details: Findings are from a prospective study that included 5142 patients with ulcerative colitis (n = 3258), Crohn’s disease (n = 1449), or unclassified IBD (n = 435) and who were compared with 450,785 non-IBD reference individuals from the UK Biobank cohort.
Disclosures: The study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Wu S et al. Inflammatory bowel disease and long-term risk of cancer: A prospective cohort study among half a million adults in UK Biobank. Inflamm Bowel Dis. 2022 (May 27). Doi: 10.1093/ibd/izac096
Key clinical point: Risk for overall cancer was 17% higher and cancer-specific mortality 26% higher in patients with inflammatory bowel disease (IBD) compared with non-IBD individuals.
Major finding: Risk for overall cancer (adjusted hazard ratio [aHR] 1.17; P < .001), particularly digestive cancer (aHR 1.33; P = .001), skin cancer (aHR 1.25; P < .001), and male genital cancer (aHR 1.29; P = .003), and cancer-specific mortality (aHR 1.26; P < .001) was significantly higher among patients with IBD vs. non-IBD individuals.
Study details: Findings are from a prospective study that included 5142 patients with ulcerative colitis (n = 3258), Crohn’s disease (n = 1449), or unclassified IBD (n = 435) and who were compared with 450,785 non-IBD reference individuals from the UK Biobank cohort.
Disclosures: The study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Wu S et al. Inflammatory bowel disease and long-term risk of cancer: A prospective cohort study among half a million adults in UK Biobank. Inflamm Bowel Dis. 2022 (May 27). Doi: 10.1093/ibd/izac096
Key clinical point: Risk for overall cancer was 17% higher and cancer-specific mortality 26% higher in patients with inflammatory bowel disease (IBD) compared with non-IBD individuals.
Major finding: Risk for overall cancer (adjusted hazard ratio [aHR] 1.17; P < .001), particularly digestive cancer (aHR 1.33; P = .001), skin cancer (aHR 1.25; P < .001), and male genital cancer (aHR 1.29; P = .003), and cancer-specific mortality (aHR 1.26; P < .001) was significantly higher among patients with IBD vs. non-IBD individuals.
Study details: Findings are from a prospective study that included 5142 patients with ulcerative colitis (n = 3258), Crohn’s disease (n = 1449), or unclassified IBD (n = 435) and who were compared with 450,785 non-IBD reference individuals from the UK Biobank cohort.
Disclosures: The study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Wu S et al. Inflammatory bowel disease and long-term risk of cancer: A prospective cohort study among half a million adults in UK Biobank. Inflamm Bowel Dis. 2022 (May 27). Doi: 10.1093/ibd/izac096